Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Avalo Therapeutics, Inc. (AVTX) had Return on Tangible Equity of -107.87% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.06M |
|
$-78.26M |
|
-- |
|
$0.06M |
|
$72.98M |
|
$-72.92M |
|
$-5.17M |
|
$-78.09M |
|
$-78.09M |
|
$-78.26M |
|
$-78.26M |
|
$-78.26M |
|
$-78.26M |
|
$-72.92M |
|
$-72.58M |
|
13.40M |
|
13.40M |
|
$-5.84 |
|
$-5.84 |
|
| Balance Sheet Financials | |
$105.29M |
|
$0.46M |
|
$11.17M |
|
$116.46M |
|
$12.94M |
|
-- |
|
$20.47M |
|
$33.41M |
|
$83.05M |
|
$72.55M |
|
$83.05M |
|
18.51M |
|
| Cash Flow Statement Financials | |
$-51.46M |
|
$-81.72M |
|
$14.59M |
|
$134.70M |
|
$16.11M |
|
$-118.59M |
|
$13.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-123601.70% |
|
-123601.70% |
|
-123018.60% |
|
-132362.70% |
|
-132642.40% |
|
$-51.46M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-94.23% |
|
|
Return on Tangible Equity |
-107.87% |
-67.20% |
|
-94.23% |
|
$4.49 |
|
$-3.84 |
|
$-3.84 |
|